Skip to content
Trial Eligibility
Menu

EHR Alerts to Improve GLP-1 Medication and Continuous Glucose Monitor Prescribing in Primary Care

NCT07948928

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

This randomized quality improvement study will evaluate whether pop-up alerts in the electronic health record (EHR) increase prescribing of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and continuous glucose monitors (CGMs) for eligible patients with diabetes. The study will be conducted at nine Montefiore Medical Group primary care sites. Primary care providers will be randomly assigned to either receive the alerts or not receive them.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus

Eligibility basics and study details

Study type
Interventional
Phase
Not applicable
Ages
18 to 85 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Montefiore Medical Center
Last updated on ClinicalTrials.gov
November 19, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

New York · 1

  • Montefiore Medical Center · The Bronx, NY

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.